In pre-clinical testing, multiple proprietary molecules "showed consistent positive results when compared to the parent molecule".
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression
Compass Pathways completes the world's largest psilocybin-based clinical trial as the 216th patient in its trial completed their treatment.
Cybin Inc. Releases Annual Financials and Provides Business Highlights
Cybin Inc releases its full-year financial results for the fiscal year ended March 31, 2021 and provides business highlights.
Psyched Wellness Commences Next Pre-Clinical Study on AME-1
Psyched Wellness announces its latest pre-clinical study on AME-1.
Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results
Field Trip reports Q4 and full-year results for fiscal 2021. Cash position of CAD$111m. Clinic revenues increased by 63% q-o-q to CAD$526,435.
Psychedelic Medicine: Will The High Always Be Part Of The Therapy?
Psychedelic Stock Watch explains why astute investors will put their dollars into both "experiential" and non-psychoactive psychedelic drug R&D.
Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board
The newest member of Cybin's Clinical Advisory Board previously held a senior position with the FDA.
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
Mydecine's novel molecule, MYCO-004 is targeting multiple forms of addiction/substance abuse.
Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species
Numinus files a patent application for a "process" that can allow faster, more cost-effective production of psychoactive compounds such as psilocybin.
Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer
Novamind's new Chief Scientific Officer is a physician with deep knowledge of psychiatry and palliative care, including familiarity with ketamine-assisted psychotherapy.
Alternatives to ATAI: Go Big Or Go Small?
Sometimes biggest is not "best". Psychedelic Stock Watch offers investors a lot of reasons why thinking SMALLER may be more profitable.
Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study
Cybin completes its 51st pre-clinical molecule study, with four of these molecules already being advanced to toward clinical evaluations.
